{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Events+Control", "query": { "condition": "Events Control" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 227, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Events+Control&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T20:22:50.525Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02540993", "title": "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5734, "start_date": "2015-09-17", "completion_date": "2020-04-14", "has_results": true, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 176, "location_summary": "Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Payne", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02540993" }, { "nct_id": "NCT02396134", "title": "Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Hodgkin Lymphoma", "Adult Non-Hodgkin Lymphoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Cytomegaloviral Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "HLA-A*0201 Positive Cells Present", "Myelodysplastic Syndrome", "Adult Lymphoblastic Lymphoma", "Chronic Lymphocytic Leukemia", "Myelofibrosis", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "CMVpp65-A*0201 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 61, "start_date": "2015-05-21", "completion_date": "2024-09-19", "has_results": true, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 5, "location_summary": "Duarte, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02396134" }, { "nct_id": "NCT04199793", "title": "Lavare Cycle in Patients Receiving HeartWare Left Ventricular Assist Device", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Thromboembolism", "Hemolysis", "Stroke" ], "interventions": [ { "name": "Lavare On", "type": "DEVICE" }, { "name": "Lavare Off", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-08-10", "completion_date": "2021-08-10", "has_results": true, "last_update_posted_date": "2022-12-12", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Oak Lawn, Illinois • Indianapolis, Indiana + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oak Lawn", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04199793" }, { "nct_id": "NCT05581303", "title": "Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Olpasiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 7297, "start_date": "2022-12-14", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 133, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 112 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05581303" }, { "nct_id": "NCT01444430", "title": "A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Symbicort pMDI", "type": "DRUG" }, { "name": "budesonide pMDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "12 Years to 130 Years" }, "enrollment_count": 12460, "start_date": "2011-12", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 160, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01444430" }, { "nct_id": "NCT00249795", "title": "Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Cardiovascular Disease" ], "interventions": [ { "name": "Irbesartan", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9016, "start_date": "2003-06", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2010-10-15", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00249795" }, { "nct_id": "NCT07000357", "title": "A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "AZD0780", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15100, "start_date": "2025-06-04", "completion_date": "2029-10-26", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 357, "location_summary": "Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Foley", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07000357" }, { "nct_id": "NCT04188379", "title": "A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immune Thrombocytopenia" ], "interventions": [ { "name": "efgartigimod", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2019-12-16", "completion_date": "2022-02-03", "has_results": true, "last_update_posted_date": "2025-03-13", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 9, "location_summary": "Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04188379" }, { "nct_id": "NCT06032546", "title": "A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immuno-deficiency Virus (HIV) Disease" ], "interventions": [ { "name": "Budigalimab", "type": "DRUG" }, { "name": "Placebo for Budigalimab", "type": "DRUG" }, { "name": "ABBV-382", "type": "DRUG" }, { "name": "Placebo for ABBV-382", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 163, "start_date": "2023-10-12", "completion_date": "2025-09-22", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06032546" }, { "nct_id": "NCT02195232", "title": "Cancer Associated Thrombosis and Isoquercetin (CATIQ)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Thromboembolism of Vein VTE in Colorectal Cancer", "Thromboembolism of Vein in Pancreatic Cancer", "Thromboembolism of Vein in Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Isoquercetin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey Zwicker, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2015-01", "completion_date": "2019-10-22", "has_results": true, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-09-02T20:22:50.525Z", "location_count": 11, "location_summary": "Los Angeles, California • Sacramento, California • West Haven, Connecticut + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "York Village", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT02195232" } ] }